论文信息 - Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report. - 字舞流文

Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.

Kenji Ashida | R. Sakamoto | N. Hasuzawa | Seiichi Yano | C. Sakaguchi | S. Sakamoto | H. Inoue | Y. Kurihara | H. Umeguchi | Hiromasa Takenoshita

[1] Y. Nakanishi,et al. Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2] E. Plimack,et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. , 2017, Cancer treatment reviews.

[3] M. Postow,et al. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. , 2016, JAMA oncology.

[4] Matthieu Texier,et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination , 2016, Nature Reviews Clinical Oncology.

[5] S. Garelli,et al. Diagnosis and classification of autoimmune parathyroid disease. , 2014, Autoimmunity reviews.